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Open acIntroduction
Endometrial cancer is themost common cancer of the female repro-
ductive system accounting for 6% of all cancers in women. Uterine
papillary serous carcinoma (UPSC) and clear cell carcinoma account
for less than 15% of all endometrial cancers but are biologically aggres-
sive tumors. Papillary serous carcinoma is thought to develop from
endometrial surface epithelium and presents histologically as complex
papillary structureswithmarked atypia. They aremore likely to present
with deep myometrial invasion, lymph node involvement, and distant
metastatic spread at presentation, compared to the more common
endometrioid cancers.
Here we describe a case of uterine papillary serous carcinomawith
recurrent metastatic disease to her lungs. Her tumor was positive for
Her-2 gene ampliﬁcation and she was offered treatment with Her-2
targeted therapy in an ongoing clinical trial. She demonstrated an ex-
cellent durable response lasting more than two years following her
initial diagnosis of metastatic disease.
Case history
Patient is a 63 year-oldwoman, gravida 2, para 1,without signiﬁcant
past medical history, who was found to have suspicious cells on a rou-
tine Pap smear in 2006. A transvaginal ultrasound showed an endome-
trial cyst and hysteroscopy revealed a polyp-like structure that was
removed. Pathology showed a cystic endometrial polyp with focalvelt Hospital Center, 1000 Tenth Avenue,
5449.
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cess under CC BY-NC-ND license .surface papillary serous carcinoma. The endometrial and endocervical
curettings also showed fragments of serous papillary carcinoma. Staging
PET/CT scan showed an enlarged endometrial cavity with no deﬁnite
mass or suspicious FDG uptake. There was no evidence of distant meta-
static disease. She underwent surgical staging comprising total abdomi-
nal hysterectomy, bilateral salpingo-oophorectomy, pelvic/paraaortic
lymph node dissection and omentectomy in September 2006. Intraoper-
atively, therewas no evidence of peritoneal carcinomatosis or suspicious
lymphadenopathy. The ﬁnal pathology revealed a 4 mmgrade 3 residual
papillary serous carcinoma without myometrial invasion. There was no
evidence of lympho-vascular invasion. The harvested pelvic and peri-
aortic lymph nodes and pelvic washings were negative for malignancy.
Shewas surgically staged FIGO stage IA and underwent adjuvant chemo-
therapy consisting of 6 cycles of Carboplatin (AUC 6) and Paclitaxel
(175 mg/m2) given once every 3 weeks, as well as vaginal brachythera-
py. She completed chemotherapy in February 2007 and a follow up PET/
CT in July 2007 revealed no evidence of disease.
She remained asymptomatic and continued with routine surveil-
lance until December 2008 when a repeat PET/CT showed new pul-
monary nodules. There was an 8×12 mm right middle lobe nodule
that was hypermetabolic with SUV of 2.4; a 4 mm nodule in the left
lower lobe; and a 6.5 mm subpleural nodule in the lingula that had
focal hypermatobolic activity withmaximal SUV of 2.3. Therewas no ev-
idence of local recurrence and no other sites of distant disease. A CT guid-
ed lung biopsy conﬁrmed the metastatic adenocarcinoma consistent
withpapillary serous carcinomaof endometrial origin (Fig. 1). She subse-
quently went on to receive four more cycles of chemotherapy with Car-
boplatin and Paclitaxel with complete resolution of the pulmonary
nodules and no new evidence of metastatic disease. The chemotherapy
was held after that secondary to grade 4 anemia and she was followed
clinically.
However, repeat scans in October 2009 showed new pulmonary
nodules consistent with recurrent disease. Her lung biopsy specimen
was found to have Her-2 gene ampliﬁcation by FISH (ﬂuorescence in
situ hybridization). As such, she was enrolled in a single arm phase II
clinical trial evaluating the role of the irreversible ErbB Family Blocker
afatinib (BIBW2992, Boehringer Ingelheim) in a variety of tumors over-
expressing EGFR or with Her-2 gene ampliﬁcation. Shewas started on a
50mg daily dose and a follow up scan after 6 weeks showed complete
response with resolution of the pulmonary nodules. Her treatment
was complicated by grade 3 diarrhea, grade 2 rash, and grade 1
mucositis, requiring a decrease in dose to 40 mg daily. Her follow up
scans at 12 weeks and at 6 months continued to show complete remis-
sion. However, shewas taken off the drug in July 2010, after 8 months of
treatment, secondary to recurrent grade 3 weight loss.
Fig. 1. Lung biopsy showing adenocarcinoma with morphology and immunohistochemi-
cal staining consistent with patient's previous papillary serous endometrial carcinoma.
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centimeter nodule in the middle lobe of right lung. She underwent
right VATS (video assisted thoracoscopic surgery)withwedge resection
of the pulmonary nodule, with pathology conﬁrming a 9 mm focus of
metastatic serous carcinoma. There was no evidence of any other sites
of metastatic disease and her subsequent scans conﬁrmed complete re-
mission. However, in June 2011, she was found to have recurrent lung
lesions andwas started on lapatinib, considering her excellent response
to previous Her-2 targeted therapy. Unfortunately, she had progressive
disease including development of brain metastases in December 2011.
She received whole brain radiation therapy and was subsequently
started on further palliative systemic chemotherapy.Discussion
Uterine papillary serous carcinoma (UPSC) and clear cell carcinoma
are biologically aggressive tumors. A SEERdatabase report of 1473UPSC
diagnosed between 1988 and 2001 showed that more than half of
patients presented with stage III/IV disease at presentation. The 5-year
disease speciﬁc survival was much lower compared to grade 3
endometrioid tumors (55% vs. 77% respectively). The standard of care
is complete surgical staging with total abdominal hysterectomy and
bilateral salpingo-oophorectomy (TAH-BSO), complete pelvic/paraaortic
dissection, omentectomy, and assessment of the peritoneal cavity in-
cluding pelvic and diaphragmatic cytology. The amount of residual dis-
ease after surgery is a strong predictor of outcome. Most of the data on
adjuvant therapy comes from retrospective analysis suggesting a beneﬁt
in terms of progression free and overall survival.Her-2 belongs to the family of epidermal growth factor receptors
and consists of a transmembrane cell surface receptor with tyrosine ki-
nase activity. Her-2 expression has been found to be a poor prognostic
factor in several cancers including breast and ovarian, however, there
is only limited data in endometrial cancers. The frequency of Her-2
overexpression in UPSC is variably reported between 17 and 50% of
the patients. A case series of 30 UPSC patients by Santin et al. showed
that Her-2 ampliﬁcation by FISHwas found in 47% of patients including
4 patients with heterogeneous expression of gene ampliﬁcation (Santin
et al., 2005). A signiﬁcantly shorter disease speciﬁc survival was found
in patients overexpressing the Her-2 gene (17% vs. 84% at 4 years). A
difference in Her-2 expression was also thought to be related to poor
prognosis in African-American compared to Caucasianwomen. Similar-
ly, a study of 68 patients with UPSC showed Her-2/neu overexpression
in 18% of patients but out of these only 2 patients showed Her-2 gene
ampliﬁcation by FISH (Slomovitz et al., 2004). Her-2/neu over-
expression was associated with a signiﬁcantly shorter overall survival
(p=.008). Grushko et al. looked at 234 patients of endometrial cancer
enrolled in GOG 177 trial (Grushko et al., 2008). 104/234 (47%) patients
were found to have 2+/3+ Her-2 overexpression by IHC. Papillary se-
rous carcinomas were more likely to express Her-2 compared to non-
serous tumors (61% vs. 41%), including a higher proportion of patients
presenting with strong (3+) overexpression (26% vs. 18%). Her-2
gene ampliﬁcation by FISH was however found to be present only in
21% of the UPSC specimens (compared to 11% of non-serous patients),
with concordance rate of 60% between IHC and FISH. Other studies
have reported higher concordance rate in UPSC patients, however, the
number of patients in these studies were small.
The data on Her-2 targeting in endometrial cancer is limited and
mostly based upon case reports. Villella et al. examined the Her-2
gene status in patients diagnosed with UPSC between 1999 and 2001
and found 5/19 (26%) patients to be positive for Her-2 overexpression
by IHC (Villella et al., 2006). Two of these patients were treated with
trastuzumab. A stage IIIC patient had stable disease for 3 months and
a patient with stage IV disease had complete response for 6 months
on trastuzumab therapy. Similarly, Santin et al. reported good clinical
response with single agent trastuzumab in two patients; one with re-
current grade 3 endometrioid adenocarcinoma treated with chemo-
therapy plus trastuzumab and the other with stage IIIC UPSC who
received upfront single agent trastuzumab (Santin et al., 2008). In con-
trast, a recent GOG study did not demonstrate any signiﬁcant activity
using single agent trastuzumab in 33 patientswithHer-2 positive endo-
metrial cancer (Fleming et al., 2010). Out of these, 11 patients had se-
rous carcinoma, though FISH was positive in 8 of these patients.
Thus, the role of Her-2 targeting in endometrial carcinoma is still un-
certain. Afatinib is a novel, potent, small-molecule tyrosine kinase in-
hibitor which irreversibly and selectively targets the ErbB family of
receptors including EGFR and Her-2. For instance, afatinib treatment in-
hibits in vitro growth of the trastuzumab-resistant SUM 190 cell line,
which overexpresses Her-2 (Hickish et al., 2009). In vivo, it has anti-
tumor activity in SUM 190 xenografts (Solca et al., 2010) as well as in
human xenograft models known to depend on ErbB signaling (Solca
et al., 2005). Afatinib has shown encouraging results in lung and breast
cancer and is currently undergoing clinical trials in several cancers. The
most common side effects of this drug include diarrhea, rash, stomatitis,
fatigue and decreased appetite, requiring a dose reduction or even
treatment discontinuation (Miller et al., 2012). There is enough evi-
dence that anti Her-2 therapy might be more beneﬁcial to patients
with UPSC or high grade endometrioid tumors. It is also possible that
it might bemore effective when given in combination with chemother-
apy as clinical trials have shown synergistic activity of trastuzumab
with other chemotherapy agents in breast cancer. We do see some du-
rable responses with anti Her-2 therapy in UPSC as seen in our patient.
We need good prospective data including patients with serous or clear
cell carcinoma or high grade endometrioid tumors to evaluate the efﬁ-
cacy of this targeted approach.
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